Natl Toxicol Program Tech Rep Ser. 2011 Aug(536):1-203.
Bis(2-chloroethoxy)methane is used as a solvent and the starting agent in the production of fungicides and polysulfide polymers. Bis(2-chloroethoxy)methane was nominated for study by the National Institute of Environmental Health Sciences because of its widespread use as a starting material to produce polysulfide elastomers, and because there were no 2-year carcinogenicity studies reported in the literature. Male and female F344/N rats and B6C3F1 mice received dermal applications of bis(2-chloroethoxy)-methane in ethanol (greater than 98% pure) for 2 weeks, 3 months, or 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium and Escherichia coli, rat bone marrow cells, and mouse peripheral blood erythrocytes. 2-WEEK STUDY IN RATS: Groups of five male and five female rats were dermally administered 0, 12.5, 25, 50, 100, or 200 mg bis(2-chloroethoxy)methane/kg body weight in ethanol, 5 days per week for 16 days. All rats survived to the end of the study. Mean body weights of dosed rats were similar to those of the vehicle control groups. There were no histopathologic lesions related to bis(2-chloroethoxy)methane administration. 2-WEEK STUDY IN MICE: Groups of five male and five female mice were dermally administered 0, 12.5, 25, 50, 100, or 200 mg bis(2-chloroethoxy)methane/kg body weight in ethanol, 5 days per week for 17 days. All mice survived to the end of the study. Mean body weights of dosed mice were similar to those of the vehicle control groups. There were no histopathologic lesions related to bis(2-chloroethoxy)methane administration. 3-MONTH STUDY IN RATS: Groups of 10 male and 10 female rats were dermally administered 0, 50, 100, 200, 400, or 600 mg bis(2-chloroethoxy)methane/kg body weight in ethanol, 5 days per week for 14 weeks. Additional clinical pathology groups of 10 male and 10 female rats were administered the same doses for 23 days. All core study 600 mg/kg males and females and two 400 mg/kg females died before the end of the study. The cause of death was considered to be related to the cardiotoxic effect of bis(2-chloroethoxy)methane. There were no significant differences between final mean body weights of dosed rats and those of the vehicle control groups; the mean body weight gain of 400 mg/kg males was significantly less than that of the vehicle controls. Clinical findings included prostration and ataxia in 600 mg/kg rats during the first week of the study and nasal/eye discharge, lethargy, ataxia, and abnormal breathing in 400 and 600 mg/kg females beginning week 5. An enlarged heart was noted in one 100 mg/kg female rat. Relative kidney weights of 100, 200, and 400 mg/kg males were significantly greater than that of the vehicle control group. Increased incidences and severities of myofiber cytoplasmic vacuolization and interstitial mononuclear cell infiltration in the heart occurred in 400 and 600 mg/kg male and female rats and in 200 mg/kg females. Increased incidences and severities of myofiber necrosis occurred in 600 mg/kg males and females; one female each in the 200 and 400 mg/kg groups also had this lesion. Three 600 mg/kg males had atrial thrombosis. 3-MONTH STUDY IN MICE: Groups of 10 male and 10 female mice were dermally administered 0, 50, 100, 200, 400, or 600 mg bis(2-chloroethoxy)methane/kg body weight in ethanol, 5 days per week for 14 weeks. Except for three 600 mg/kg females, all mice survived to the end of the study. Mean body weights of dosed and vehicle control mice were similar. One 600 mg/kg female that died early exhibited lethargy, abnormal breathing, and tremors, and one animal had clonic seizures. One 600 mg/kg female that died early had focal erosion of the glandular stomach and a focus in the duodenum found to consist of acute suppurative inflammation and thrombosis. Absolute and relative kidney weights of 400 and 600 mg/kg males and 600 mg/kg females were significantly greater than those of the vehicle control groups. Absolute liver weights of 400 and 600 mg/kg females were also significantly increased. Significantly increased incidences of myofiber cytoplasmic vacuolization occurred in 400 and 600 mg/kg females. 2-YEAR STUDY IN RATS: Groups of 50 male and 50 female rats were dermally administered 0, 75, 150, or 300 mg bis(2-chloroethoxy)methane/kg body weight in ethanol, 5 days per week for 105 weeks. Survival of all dosed groups of rats was generally similar to that of the vehicle controls. Mean body weights of dosed rats were similar to those of the vehicle controls throughout the study. Clinical findings in 300 mg/kg females that died during the first year of the study included abnormal breathing, lethargy, thinness, nasal discharge, and ataxia. Significantly increased incidences of degeneration of the olfactory epithelium in the nose occurred in all dosed groups of males and in 150 and 300 mg/kg females. The incidences of inflammation of the forestomach were significantly increased in 150 and 300 mg/kg males, and the incidence of ulcers was significantly increased in 300 mg/kg males. Increased incidences of cystic degeneration of the liver occurred in 150 and 300 mg/kg male rats; the incidence was significantly increased in the 300 mg/kg group. 2-YEAR STUDY IN MICE: Groups of 50 male mice were dermally administered 0, 150, 300, or 600 mg bis(2-chloroethoxy)methane/kg body weight in ethanol, 5 days per week for 105 weeks. Groups of 50 female mice were dermally administered 0, 100, 200, or 400 mg/kg in ethanol, 5 days per week for 104 weeks. Survival of 600 mg/kg male mice was significantly less than that of the vehicle control group. Mean body weights of dosed mice were generally similar to those of the vehicle controls throughout the study. Clinical findings observed in 600 mg/kg male mice that died during the first year of the study included lethargy and thinness. Myocardial heart changes were recorded according to the characteristic lesions of cardiomyopathy syndrome (necrosis, mononuclear cell infiltration, myocardial cell vacuolization, and interstitial fibrosis) separately, and in addition, where appropriate, they were also categorized as cardiomyopathy. Increased incidences of cardiomyopathy and mononuclear cell infiltration occurred in 600 mg/kg males and 400 mg/kg females; the incidences were significantly increased in 600 mg/kg males compared to the vehicle controls. Significantly increased incidences of cardiomyocyte vacuolization and interstitial fibrosis occurred in 600 mg/kg males. A few early deaths in the 600 mg/kg males were considered to be due, at least in part and probably exclusively, to bis(2-chloroethoxy)methane-induced cardiotoxicity. The incidence of ulceration of the forestomach was significantly increased in 600 mg/kg males. Significantly increased incidences of dermal inflammation and fibrosis and epidermal hyperplasia at the site of application occurred in 600 mg/kg male mice.
Bis(2-chloroethoxy)methane was mutagenic in S. typhimurium strains TA100 and TA1535 in the presence of exogenous metabolic activation enzymes (S9) in one study; results from a second bacterial mutagenicity test were judged to be equivocal based on responses observed in TA100 and in E. coli strain WP2 uvrA/pKM101 in the presence of S9. No mutagenicity was observed in other tester strains or in the absence of S9. Bis(2-chloroethoxy)methane did not increase the frequency of micronucleated reticulocytes in bone marrow of male F344/N rats following three daily treatments by gavage or micronucleated erythrocytes in peripheral blood of male or female mice after 3 months of dermal exposure.
Under the conditions of these 2-year dermal studies, there was no evidence of carcinogenic activity of bis(2-chloroethoxy)methane in male or female F344/N rats administered 75, 150, or 300 mg/kg. There was no evidence of carcinogenic activity of bis(2-chloroethoxy)methane in male B6C3F1 mice administered 150, 300, or 600 mg/kg or in female B6C3F1 mice administered 100, 200, or 400 mg/kg. The administration of bis(2-chloroethoxy)methane for 2 years resulted in increased incidences of nonneoplastic lesions in the nose of male and female rats, the forestomach of male rats, the heart of male and female mice, and the forestomach and skin of male mice.
双(2-氯乙氧基)甲烷用作溶剂以及生产杀菌剂和聚硫化物聚合物的起始剂。双(2-氯乙氧基)甲烷因其作为生产聚硫化物弹性体的起始材料被广泛使用,且文献中未报道过两年期致癌性研究,故而被美国国家环境卫生科学研究所指定进行研究。雄性和雌性F344/N大鼠以及B6C3F1小鼠接受了双(2-氯乙氧基)甲烷在乙醇(纯度大于98%)中的皮肤涂抹,持续2周、3个月或2年。在鼠伤寒沙门氏菌、大肠杆菌、大鼠骨髓细胞和小鼠外周血红细胞中进行了遗传毒理学研究。
将每组五只雄性和五只雌性大鼠,以0、12.5、25、50、100或200毫克双(2-氯乙氧基)甲烷/千克体重的剂量,溶于乙醇中,每周5天,持续16天进行皮肤给药。所有大鼠均存活至研究结束。给药大鼠的平均体重与赋形剂对照组相似。未发现与双(2-氯乙氧基)甲烷给药相关的组织病理学损伤。
将每组五只雄性和五只雌性小鼠,以0、12.5、25、50、100或200毫克双(2-氯乙氧基)甲烷/千克体重的剂量,溶于乙醇中,每周5天,持续17天进行皮肤给药。所有小鼠均存活至研究结束。给药小鼠的平均体重与赋形剂对照组相似。未发现与双(2-氯乙氧基)甲烷给药相关的组织病理学损伤。
将每组10只雄性和10只雌性大鼠,以0、50、100、200、400或600毫克双(2-氯乙氧基)甲烷/千克体重的剂量,溶于乙醇中,每周5天,持续14周进行皮肤给药。另外10只雄性和10只雌性大鼠的临床病理学分组,以相同剂量给药23天。所有核心研究中,600毫克/千克组的雄性和雌性以及两只400毫克/千克组的雌性在研究结束前死亡。死亡原因被认为与双(2-氯乙氧基)甲烷的心脏毒性作用有关。给药大鼠的最终平均体重与赋形剂对照组之间无显著差异;400毫克/千克组雄性的平均体重增加显著低于赋形剂对照组。临床发现包括,在研究的第一周,600毫克/千克组大鼠出现虚脱和共济失调,从第5周开始,400和600毫克/千克组雌性出现鼻/眼分泌物、嗜睡、共济失调和呼吸异常。在一只100毫克/千克组雌性大鼠中发现心脏增大。100、200和400毫克/千克组雄性的相对肾脏重量显著高于赋形剂对照组。400和600毫克/千克组的雄性和雌性大鼠以及200毫克/千克组的雌性大鼠,心脏肌纤维细胞质空泡化和间质单核细胞浸润的发生率和严重程度增加。600毫克/千克组的雄性和雌性大鼠肌纤维坏死的发生率和严重程度增加;200和400毫克/千克组各有一只雌性也有此病变。三只600毫克/千克组雄性大鼠出现心房血栓形成。
将每组10只雄性和10只雌性小鼠,以0、50、100、200、400或600毫克双(2-氯乙氧基)甲烷/千克体重的剂量,溶于乙醇中,每周5天,持续14周进行皮肤给药。除三只600毫克/千克组雌性小鼠外,所有小鼠均存活至研究结束。给药小鼠和赋形剂对照小鼠的平均体重相似。一只早期死亡的600毫克/千克组雌性小鼠表现出嗜睡、呼吸异常和震颤,另一只动物出现阵挛性惊厥。一只早期死亡的600毫克/千克组雌性小鼠,腺胃有局灶性糜烂,十二指肠有一处病灶,发现由急性化脓性炎症和血栓形成组成。400和600毫克/千克组雄性以及600毫克/千克组雌性的绝对和相对肾脏重量显著高于赋形剂对照组。400和600毫克/千克组雌性的绝对肝脏重量也显著增加。400和600毫克/千克组雌性小鼠肌纤维细胞质空泡化的发生率显著增加。
将每组50只雄性和50只雌性大鼠,以0、75、150或300毫克双(2-氯乙氧基)甲烷/千克体重的剂量,溶于乙醇中,每周5天,持续105周进行皮肤给药。所有给药组大鼠的存活率一般与赋形剂对照组相似。在整个研究过程中,给药大鼠的平均体重与赋形剂对照组相似。在研究第一年死亡的300毫克/千克组雌性大鼠的临床发现包括呼吸异常、嗜睡、消瘦、鼻分泌物和共济失调。所有给药组雄性以及150和300毫克/千克组雌性大鼠鼻腔嗅上皮变性的发生率显著增加。150和300毫克/千克组雄性大鼠前胃炎症的发生率显著增加,300毫克/千克组雄性大鼠溃疡的发生率显著增加。150和300毫克/千克组雄性大鼠肝脏囊性变性的发生率增加;300毫克/千克组的发生率显著增加。
将每组50只雄性小鼠,以0、150、300或600毫克双(2-氯乙氧基)甲烷/千克体重的剂量,溶于乙醇中,并每周5天,持续105周进行皮肤给药。将每组50只雌性小鼠,以0、100、200或400毫克/千克的剂量,溶于乙醇中,并每周5天,持续104周进行皮肤给药。600毫克/千克组雄性小鼠的存活率显著低于赋形剂对照组。在整个研究过程中,给药小鼠的平均体重一般与赋形剂对照组相似。在研究第一年死亡的600毫克/千克组雄性小鼠的临床发现包括嗜睡和消瘦。根据心肌病综合征的特征性病变(坏死、单核细胞浸润、心肌细胞空泡化和间质纤维化)分别记录心肌变化,此外,在适当情况下,它们也被归类为心肌病。600毫克/千克组雄性和400毫克/千克组雌性心肌病和单核细胞浸润的发生率增加;与赋形剂对照组相比,600毫克/千克组雄性的发生率显著增加。600毫克/千克组雄性心肌细胞空泡化和间质纤维化的发生率显著增加。600毫克/千克组雄性的一些早期死亡至少部分且可能完全归因于双(2-氯乙氧基)甲烷诱导的心脏毒性。600毫克/千克组雄性大鼠前胃溃疡的发生率显著增加。600毫克/千克组雄性小鼠给药部位皮肤炎症、纤维化和表皮增生的发生率显著增加。
在一项研究中,双(2-氯乙氧基)甲烷在存在外源性代谢激活酶(S9)的情况下,对鼠伤寒沙门氏菌TA100和TA1535菌株具有致突变性;基于在TA100和大肠杆菌WP2 uvrA/pKM101菌株中存在S9时观察到的反应,第二项细菌致突变性试验的结果被判定为不明确。在其他测试菌株中或不存在S9时未观察到致突变性。在雄性F344/N大鼠经口每日给药三天后,双(2-氯乙氧基)甲烷未增加骨髓中微核网织红细胞的频率,在雄性或雌性小鼠皮肤暴露3个月后,也未增加外周血中微核红细胞的频率。
在这些两年期皮肤研究的条件下,未发现给予75、150或300毫克/千克双(2-氯乙氧基)甲烷的雄性或雌性F344/N大鼠有致癌活性证据。未发现给予150、300或600毫克/千克双(2-氯乙氧基)甲烷的雄性B6C3F1小鼠或给予100、200或400毫克/千克双(2-氯乙氧基)甲烷的雌性B6C3F1小鼠有致癌活性证据。给予双(2-氯乙氧基)甲烷两年导致雄性和雌性大鼠鼻腔、雄性大鼠前胃、雄性和雌性小鼠心脏以及雄性小鼠前胃和皮肤非肿瘤性病变的发生率增加。